Sudden hearing loss due to oxaliplatin use in a patient with colon cancer

Güvenç, M. Güven; Dizdar, Denizhan; Dizdar, Senem Kurt; Okutur, Sadi Kerem; Demir, Gökhan

doi:10.1179/1973947815y.0000000023

Cited by 15 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Malhotra et al 3 reported the first case of ototoxicity, which occurred after a single intravenous infusion of oxaliplatin for a colorectal malignancy. Of the five cases reported, hearing loss developed in four cases, 1,4,3,12 and three cases, unfortunately, resulted in irreversible hearing damage, as in the present case. 3,4,12 In one case of hearing loss, the patient continued chemotherapy with oxaliplatin even after developing hearing loss, and the hearing loss was irreversible.…”

Section: 11supporting

confidence: 63%

“…Of the five cases reported, hearing loss developed in four cases, 1,4,3,12 and three cases, unfortunately, resulted in irreversible hearing damage, as in the present case. 3,4,12 In one case of hearing loss, the patient continued chemotherapy with oxaliplatin even after developing hearing loss, and the hearing loss was irreversible. 4 In the other three cases of hearing loss, chemotherapy with oxaliplatin was discontinued, and slight improvement of hearing loss was noted only in one case.…”

Section: 11supporting

confidence: 63%

“…4 In the other three cases of hearing loss, chemotherapy with oxaliplatin was discontinued, and slight improvement of hearing loss was noted only in one case. 1,3,12 Even after discontinuing oxaliplatin after the development of hearing loss, recovery from hearing loss was not observed in current case. A decision about whether to switch or discontinue chemotherapy after ototoxicity should be made using a multidisciplinary approach.…”

Section: 11mentioning

confidence: 53%

See 2 more Smart Citations

Oxaliplatin-induced Sudden Hearing Loss in a Patient with Pancreatic Cancer

Kim

et al. 2020

Korean J Gastroenterol

View full text Add to dashboard Cite

Oxaliplatin is a new generation of platinum derivatives used frequently to treat solid organ malignancies, including colorectal and ovarian cancer. Recently, an oxaliplatin-based chemotherapeutic regimen was adopted for advanced pancreatic cancer. Although oxaliplatin has extensive therapeutic potential, its use can be limited by significant adverse effects, particularly ototoxicity. This paper reports a rare case of irreversible unilateral hearing loss in a 48-year-old female that developed after the intravenous infusion of oxaliplatin during pancreatic cancer treatment. To the best of the authors' knowledge, this is the second reported case of oxaliplatin-related ototoxicity in pancreatic cancer.

show abstract

Section: 11supporting

confidence: 63%

Section: 11supporting

confidence: 63%

Section: 11mentioning

confidence: 53%

See 1 more Smart Citation

Oxaliplatin-induced Sudden Hearing Loss in a Patient with Pancreatic Cancer

Kim

et al. 2020

Korean J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Peripheral neurotoxicity is a dose-limiting side effect of oxaliplatin (Stefansson and Nygren 2016 ; Gamelin et al 2002 ; Saif and Reardon 2005 ). Despite some reports of isolated instances of oxaliplatin-induced hearing loss (Guvenc et al 2016 ; Oh et al 2013 ), oxaliplatin is considered non-ototoxic in humans (Pasetto et al 2006 ; Yuce et al 2014 ). When oxaliplatin is applied directly to rat organ of Corti cultures, the observed cochlear damage is comparable with that caused by cisplatin (Dammeyer et al 2014 ; Dalian et al 2013 ), suggesting that oxaliplatin may not cross the blood-labyrinth barrier and may therefore be excluded from the cochlea when administered systemically (Hellberg et al 2009 ).…”

Section: Introductionmentioning

confidence: 99%

Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents

Gersten

Fitzgerald

Fernandez

et al. 2020

JARO

View full text Add to dashboard Cite

Cisplatin is a widely used anti-cancer drug used to treat a variety of cancer types. One of the side effects of this life-saving drug is irreversible ototoxicity, resulting in permanent hearing loss in many patients. In order to understand why cisplatin is particularly toxic to the inner ear, we compared the hearing loss and cochlear uptake of cisplatin to that of two related drugs, carboplatin and oxaliplatin. These three drugs are similar in that each contains a core platinum atom; however, carboplatin and oxaliplatin are considered less ototoxic than cisplatin. We delivered these three drugs to mice using a 6-week cyclic drug administration protocol. We performed the experiment twice, once using equimolar concentrations of the drugs and once using concentrations of the drugs more proportional to those used in the clinic. For both concentrations, we detected a significant hearing loss caused by cisplatin and no hearing loss caused by carboplatin or oxaliplatin. Cochlear uptake of each drug was measured using inductively coupled plasma mass spectrometry (ICP-MS) to detect platinum. Cochlear platinum levels were highest in mice treated with cisplatin followed by oxaliplatin, while carboplatin was largely excluded from the cochlea. Even when the drug doses were increased, cochlear platinum remained low in mice treated with oxaliplatin or carboplatin. We also examined drug clearance from the inner ear by measuring platinum levels at 1 h and 24 h after drug administration. Our findings suggest that the reduced cochlear platinum we observed with oxaliplatin and carboplatin were not due to increased clearance of these drugs relative to cisplatin. Taken together, our data indicate that the differential ototoxicity among cisplatin, carboplatin, and oxaliplatin is attributable to differences in cochlear uptake of these three drugs.

show abstract

“…12) Approximately 25 to 30% patients develop chronic neuropathy after continued oxaliplatin treatment due to pooled toxicity which results in pain and loss of sensation. 13) In addition, it is also associated with rare cases of ototoxicity 14,15) and hepatotoxicity. 16,17) It has also been reported that highly toxic DNA lesions are caused by oxaliplatin based therapy at the cellular level 18) and may result in DNA damage and therefore higher risk for development of secondary malignancies.…”

Section: Introductionmentioning

confidence: 99%

The Protective Effect of Naringenin on Oxaliplatin-Induced Genotoxicity in Mice

Ganaie

Jan

Khan

et al. 2019

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

Oxaliplatin is a third generation platinum based anti-cancer drug used against various human malignancies but displays genotoxic properties against normal cells. Naringenin is a naturally occurring bioflavonoid that possesses anti-oxidant properties and has protective effects against DNA damage. The aim of this study is to examine the protective effects of naringenin on oxaliplatin-induced DNA damage in mice. A total of 50, male BALB/c mice were randomly divided equally into five groups. Oxaliplatin toxicity was induced by a single dose (7 mg/kg body weight (b.w.)) injection (intraperitoneally (i.p.)) of oxaliplatin. Naringenin was given orally for ten consecutive days at two doses, 20 mg/kg b.w. (dose I) and 40 mg/kg b.w. (dose II), to group I and group II, respectively. On the tenth day of the experiment, animals in groups III, IV, and V were given a single i.p. injection of oxaliplatin (7 mg/kg b.w.). All the animals were sacrificed 24 h after oxaliplatin treatment. The extent of genotoxicity was assessed by multiple genotoxicity assays (8-hydroxydeoxy-guanosine marker, comet, micronucleus and chromosomal aberration assays, oxidative stress-marker Glutathione evaluation) in order to determine diverse kinds of DNA damage. The results indicated that naringenin administration significantly reduced the DNA damage induced by oxaliplatin possibly due to its strong anti-oxidant properties. The results suggest that naringenin is a potential candidate for future development as a chemoprotective agent against chemotherapy associated complications.

show abstract

Sudden hearing loss due to oxaliplatin use in a patient with colon cancer

Cited by 15 publications

References 8 publications

Oxaliplatin-induced Sudden Hearing Loss in a Patient with Pancreatic Cancer

Oxaliplatin-induced Sudden Hearing Loss in a Patient with Pancreatic Cancer

Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents

The Protective Effect of Naringenin on Oxaliplatin-Induced Genotoxicity in Mice

Contact Info

Product

Resources

About